Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
More than 70% of patients with Type 2 diabetes mellitus (T2DM) die because of cardiovascular diseases. Current therapeutic strategies are based on separate treatment of insulin resistance and dyslipidaemia. Development of drugs with multimodal activities should improve management of the global cardiovascular risk of T2DM patients and result in better patient compliance. New therapeutic strategies are aimed at targeting the entire spectrum of dysfunctioning organs, cells and regulatory pathways implicated in the pathogenesis of T2DM, dyslipidaemia and atherosclerosis. PPAR family members play major roles in the regulation of lipid metabolism, glucose homeostasis and inflammatory processes, making these transcription factors ideal targets for therapeutic strategies against these diseases. This review discusses why PPARs and development of novel selective PPAR modulators, dual and pan PPAR agonists constitute promising approaches for the treatment of diabetes, dyslipidaemia and atherosclerosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703 · cited 1×
“The decrease of cholesterol synthesis leads to an increased clearance of proatherogenic LDL particles due to the induction of the LDL receptor [42].”
BackgroundMultifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378 · cited 1×
“3 PPAR-γ and hypertension Recent clinical trials have suggested that certain antihypertensive agents may reduce the risk of T2DM [111].”
BackgroundYamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., et al. (2002) · Nature Medicine · doi:10.1038/nm788 · Cited by 4,238 · cited 2×
“As a consequence, AMP kinase is phosphorylated, as shown in vivo and in vitro, thus inducing acetyl-CoA carboxylase inhibition via phosphorylation [109].”
BackgroundDormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
The mechanisms of action of PPARs
Berger, J., & Moller, D. E. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.104018 · Cited by 2,659 · cited 1×
“Moreover, PPAR-γ activation induces fatty acid-binding protein, acyl-CoA synthetase, liver X receptor (LXR)α and lipoprotein lipase gene expression in adipocytes [87,88].”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965 · cited 1×
“Mast cell granules are rich in heparin proteoglycans, which interact with apoB-100, enhancing low-density lipoprotein (LDL) retention [12,13].”
BackgroundThe Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin
Shaw, R. J., Lamia, K. A., Vasquez, D., Koo, S.-H., Bardeesy, N., DePinho, R. A., Montminy, M., & Cantley, L. C. (2005) · Science · doi:10.1126/science.1120781 · Cited by 1,950 · cited 1×
“Metformin activates the AMP kinase pathway via activation of the serine/threonine kinase LKB1, leading to the decrease of hepatic gluconeogenesis and glucose output [26].”
BackgroundMcGarry, J. D. (2002) · Diabetes · doi:10.2337/diabetes.51.1.7 · Cited by 1,435
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347 · cited 2×
“PPAR-γ is also a key regulator of cholesterol homeostasis and particularly enhances the reverse cholesterol transport (RCT) pathway, as ATP-binding cassette A1 (ABCA-1), SR-B1 and CD36 are target genes [83,84].”
BackgroundPathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Griffin, M. E., Marcucci, M. J., Cline, G. W., Bell, K., Barucci, N., Lee, D., Goodyear, L. J., Kraegen, E. W., White, M. F., & Shulman, G. I. (1999) · Diabetes · doi:10.2337/diabetes.48.6.1270 · Cited by 1,267
Schoonjans, K., Staels, B., & Auwerx, J. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42003-6 · Cited by 1,216
Self-citationCusi, K., Maezono, K., Osman, A., Pendergrass, M., Patti, M. E., Pratipanawatr, T., DeFronzo, R. A., Kahn, C. R., & Mandarino, L. J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci7535 · Cited by 1,139 · cited 1×
“2 PPAR-γ and peripheral insulin sensitivity Even if the molecular mechanisms are not fully understood, insulin resistance can be defined as a disruption of insulin receptor signalling pathway in skeletal muscle, hepatocytes and adipocytes [81,82].”
BackgroundInterleukin-6 induces cellular insulin resistance in hepatocytes.
Senn, J. J., Klover, P. J., Nowak, I. A., & Mooney, R. A. (2002) · Diabetes · doi:10.2337/diabetes.51.12.3391 · Cited by 883 · cited 1×
“IL-6 also reduces insulin signalling through downregulation of insulin receptor substrate-1 and Akt [96-99], an effect that can be suppressed by TZD treatment [100].”
BackgroundDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774 · cited 1×
“In patients with low HDL levels, treatment with torcetrapib alone or in combination with a statin increased HDL and decreased LDL levels [47].”
BackgroundTherapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
Self-citationPPAR : a dagger in the heart of the metabolic syndrome
Barish, G. D. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27955 · Cited by 641 · cited 1×
“PPAR-β/δ agonists seem to be indicated in the metabolic syndrome treatment [64].”
BackgroundGuerre-Millo, M., Gervois, P., Raspé, E., Madsen, L., Poulain, P., Derudas, B., Herbert, J.-M., Winegar, D. A., Willson, T. M., Fruchart, J.-C., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.22.16638 · Cited by 605 · cited 1×
“PPAR-α activation by agonist treatment in diabetic mouse models improves glucose homeostasis in skeletal muscle, liver and pancreas [70,73,74].”
BackgroundSelf-citationStephens, J. M., Lee, J., & Pilch, P. F. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.2.971 · Cited by 553
Combs, T. P., Pajvani, U. B., Berg, A. H., Lin, Y., Jelicks, L. A., Laplante, M., Nawrocki, A. R., Rajala, M. W., Parlow, A. F., Cheeseboro, L., et al. (2004) · Endocrinology · doi:10.1210/en.2003-1068 · Cited by 545 · cited 1×
“Moreover, adiponectin decreases phosphoenolpyruvate carboxy kinase and glucose-6-phosphatase activities, thus inhibiting gluconeogenesis and glucose output in liver [108].”
BackgroundDisruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E–deficient mice
Cyrus, T., Witztum, J. L., Rader, D. J., Tangirala, R., Fazio, S., Linton, M. F., & Funk, C. D. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5897 · Cited by 523 · cited 2×
“LDLs, oxidised by reactive oxygen species, are recognised by SR-A resulting in efficient uptake by macrophages, thus forming foam cells following accumulation of cholesteryl esters by the action of acyl-CoA:cholesterol acyltransferase [16,17].”
BackgroundIslet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes.
Kahn, S. E., Andrikopoulos, S., & Verchere, C. B. (1999) · Diabetes · doi:10.2337/diabetes.48.2.241 · Cited by 488 · cited 1×
“Emerging Drugs (2006) 11(3) 385 combination of amylin hypersecretion with elevated plasma FFA levels may impair insulin secretion and cause β-cell injury [79].”
BackgroundChinetti, G., Gbaguidi, F. G., Griglio, S., Mallat, Z., Antonucci, M., Poulain, P., Chapman, J., Fruchart, J.-C., Tedgui, A., Najib-Fruchart, J., et al. (2000) · Circulation · doi:10.1161/01.cir.101.20.2411 · Cited by 428
Self-citationThe Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages
Vosper, H., Patel, L., Graham, T. L., Khoudoli, G. A., Hill, A., Macphee, C. H., Pinto, I., Smith, S. A., Suckling, K. E., Wolf, C. R., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108482200 · Cited by 268 · cited 4×
“et al.: A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.”
BackgroundInfluentialPPAR-α–Null Mice Are Protected From High-Fat Diet–Induced Insulin Resistance
Guerre-Millo, M., Rouault, C., Poulain, P., André, J., Poitout, V., Peters, J. M., Gonzalez, F. J., Fruchart, J.-C., Reach, G., & Staels, B. (2001) · Diabetes · doi:10.2337/diabetes.50.12.2809 · Cited by 241 · cited 1×
“1 PPAR-α and glucolipotoxicity PPAR-α-deficient mice are more insulin sensitive and protected from insulin resistance when fed a high-fat diet, but suffer from severe hyperinsulinaemic hypoglycaemia following fasting [65,66].”
BackgroundSelf-citationPratipanawatr, W., Pratipanawatr, T., Cusi, K., Berria, R., Adams, J. M., Jenkinson, C. P., Maezono, K., DeFronzo, R. A., & Mandarino, L. J. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2572 · Cited by 118 · cited 1×
“2 PPAR-γ and peripheral insulin sensitivity Even if the molecular mechanisms are not fully understood, insulin resistance can be defined as a disruption of insulin receptor signalling pathway in skeletal muscle, hepatocytes and adipocytes [81,82].”
BackgroundFurther evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin
Abbasi, F., Carantoni, M., Chen, Y. D. I., & Reaven, G. M. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1301 · Cited by 72 · cited 1×
“Metformin also reduces FFA release by inhibiting lipolysis in adipose tissue [27].”
Background
Cited by
Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
Artasensi, A., Pedretti, A., Vistoli, G., & Fumagalli, L. (2020) · Molecules · doi:10.3390/molecules25081987 · Cited by 494
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Self-citationFruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260
“This PPAR-RXR complex then recognises and binds to specific PPAR response elements, leading to modulation of expression of the target genes influencing, for isotype α, fatty acid oxidation, lipid metabolism, energy balance and inflammation.(135)”
BackgroundSelf-citationFibrates and future PPARα agonists in the treatment of cardiovascular disease
Staels, B., Maes, M., & Zambon, A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1278 · Cited by 160
Self-citationBouhlel, M. A., Staels, B., & Chinetti‐Gbaguidi, G. (2008) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01892.x · Cited by 51
Self-citation
Metadata
- Authors
- Pourcet, B., Fruchart, J.-C., Staels, B., & Glineur, C.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa Healthcare
- Published
- 2006-08-29
- Volume
- 11
- Issue
- 3
- Pages
- 379-401
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2118763228
- Cited by
- 98
- References
- 31
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.